Marinova Pty Ltd

Cambridge, Australia

Marinova Pty Ltd

Cambridge, Australia
Time filter
Source Type

Fitton J.H.,Marinova Pty Ltd. | Stringer D.N.,Marinova Pty Ltd. | Karpiniec S.S.,Marinova Pty Ltd.
Marine Drugs | Year: 2015

Fucoidans are a class of sulfated fucose-rich polysaccharides found in brown marine algae and echinoderms. Fucoidans have an attractive array of bioactivities and potential applications including immune modulation, cancer inhibition, and pathogen inhibition. Research into fucoidan has continued to gain pace over the last few years and point towards potential therapeutic or adjunct roles. The source, extraction, characterization and detection of fucoidan is discussed. © 2015 by the authors; licensee MDPI, Basel, Switzerland.

Fitton J.H.,Marinova Pty Ltd.
Marine Drugs | Year: 2011

Published research on fucoidans increased three fold between 2000 and 2010. These algal derived marine carbohydrate polymers present numerous valuable bioactivities. This review discusses the role for fucoidan in the control of acute and chronic inflammation via selectin blockade, enzyme inhibition and inhibiting the complement cascade. The recent data on toxicology and uptake of fucoidan is detailed together with a discussion on the comparative activities of fractions of fucoidan from different sources. Recent in vivo, in vitro and clinical research related to diverse clinical needs is discussed. Targets include osteoarthritis, kidney and liver disease, neglected infectious diseases, hemopoietic stem cell modulation, protection from radiation damage and treatments for snake envenomation. In recent years, the production of well characterized reproducible fucoidan fractions on a commercial scale has become possible making therapies from fucoidan a realizable goal. © 2011 by the authors; licensee MDPI.

Felisilda B.M.B.,Curtin University Australia | Alvarez De Eulate E.,Curtin University Australia | Stringer D.N.,Marinova Pty Ltd. | Fitton J.H.,Marinova Pty Ltd. | Arrigan D.W.M.,Curtin University Australia
Analyst | Year: 2017

Fucoidans are sulfated polysaccharides mostly derived from algae and used in a number of applications (e.g. nutrition, cosmetics, pharmaceuticals and biomaterials). In this study, the electrochemical behaviour of fucoidans extracted from two algal species (Undaria pinnatifida and Fucus vesiculosus) was assessed using voltammetry at an array of micro-interfaces formed between two immiscible electrolyte solutions (μITIES) in which the organic electrolyte phase was gelled. Cyclic voltammetry revealed an adsorption process when scanning to negative potentials, followed by a desorption peak at ca. -0.50 V on the reverse scan, indicating the electroactivity of both fucoidans. U. pinnatifida fucoidan showed a more intense voltammetric signal compared to F. vesiculosus fucoidan. In addition, use of tridodecylmethylammonium (TDMA+) or tetradodecylammonium (TDDA+) as the organic phase electrolyte cation provided improved detection of both fucoidans relative to the use of bis(triphenylphosphoranylidene)ammonium (BTPPA+) cation. Application of adsorptive stripping voltammetry provided a linear response of current with fucoidan concentration in the range 2-20 μg mL-1 for U. pinnatifida fucoidan (with TDMA+) and 10-100 μg mL-1 for F. vesiculosus fucoidan (with TDDA+). The combination of TDMA+ in the organic phase and adsorptive pre-concentration for 180 s afforded a detection limit of 1.8 μg mL-1 fucoidan (U. pinnatifida) in aqueous phase of 10 mM NaOH and 2.3 μg mL-1 in synthetic urine (pH adjusted). These investigations demonstrate the electroactivity of fucoidans at the μITIES array and provide scope for their detection at low μg mL-1 concentrations using this approach. © 2017 The Royal Society of Chemistry.

PubMed | University of Sydney, Marinova Pty Ltd and Southern Cross University of Australia
Type: | Journal: Biologics : targets & therapy | Year: 2016

Preliminary investigation of a fucoidan with demonstrated reduction in the symptoms of osteoarthritis (OA) of the hip and knee.A double-blind randomized controlled trial was carried out to determine the safety and efficacy of a 300 mg dose of a Fucus vesiculosus extract (85% fucoidan) over a 12-week period in a population (n=122) with mild-to-moderate OA of the hip and knee as measured by the validated instrument Comprehensive Osteoarthritis Test. Safety was measured by assessing cholesterol, liver function, renal function, and hematopoietic function, and closely monitoring adverse events.Ninety-six participants completed the study. The reduction in symptoms of OA was not significantly different from the placebo response. There were no changes in the blood measurements that were of any clinical significance during the course of the study.The F. vesiculosus fucoidan extract was safe and well tolerated. At a dose of 300 mg, the extract showed no difference in reduction of OA symptoms from the placebo.

PubMed | Marinova Pty Ltd. and University of Tasmania
Type: Journal Article | Journal: Journal of cellular physiology | Year: 2015

Fucoidan, a natural component of seaweeds, is reported to have immunomodulatory and anti-tumor effects. The mechanisms underpinning these activities remain poorly understood. In this study, the cytotoxicity and anti-tumor activities of fucoidan were investigated in acute myeloid leukemia (AML) cells. The human AML cell lines NB4, KG1a, HL60, and K562 were treated with fucoidan and cell cycle, cell proliferation, and expression of apoptotic pathways molecules were analyzed. Fucoidan suppressed the proliferation and induced apoptosis through the intrinsic and extrinsic pathways in the acute promyelocytic leukemia (APL) cell lines NB4 and HL60, but not in KG1a and K562 cells. In NB4 cells, apoptosis was caspase-dependent as it was significantly attenuated by pre-treatment with a pan-caspase inhibitor. P21/WAF1/CIP1 was significantly up-regulated leading to cell cycle arrest. Fucoidan decreased the activation of ERK1/2 and down-regulated the activation of AKT through hypo-phosphorylation of Thr(308) residue but not Ser(473). In vivo, a xenograft model using the NB4 cells was employed. Mice were fed with fucoidan and tumor growth was measured following inoculation with NB4 cells. Subsequently, splenic natural killer (NK) cell cytotoxic activity was also examined. Oral doses of fucoidan significantly delayed tumor growth in the xenograft model and increased cytolytic activity of NK cells. Taken together, these data suggest that the selective inhibitory effect of fucoidan on APL cells and its protective effect against APL development in mice warrant further investigation of fucoidan as a useful agent in treatment of certain types of leukemia.

PubMed | Marinova Pty Ltd, University of Tasmania and University Technology of MARA
Type: Journal Article | Journal: PloS one | Year: 2015

Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohns disease, are an important cause of morbidity and impact significantly on quality of life. Overall, current treatments do not sustain a long-term clinical remission and are associated with adverse effects, which highlight the need for new treatment options. Fucoidans are complex sulphated, fucose-rich polysaccharides, found in edible brown algae and are described as having multiple bioactivities including potent anti-inflammatory effects. Therefore, the therapeutic potential of two different fucoidan preparations, fucoidan-polyphenol complex (Maritech Synergy) and depyrogenated fucoidan (DPF) was evaluated in the dextran sulphate sodium (DSS) mouse model of acute colitis. Mice were treated once daily over 7 days with fucoidans via oral (Synergy or DPF) or intraperitoneal administration (DPF). Signs and severity of colitis were monitored daily before colons and spleens were collected for macroscopic evaluation, cytokine measurements and histology. Orally administered Synergy and DPF, but not intraperitoneal DPF treatment, significantly ameliorated symptoms of colitis based on retention of body weight, as well as reduced diarrhoea and faecal blood loss, compared to the untreated colitis group. Colon and spleen weight in mice treated with oral fucoidan was also significantly lower, indicating reduced inflammation and oedema. Histological examination of untreated colitis mice confirmed a massive loss of crypt architecture and goblet cells, infiltration of immune cells and oedema, while all aspects of this pathology were alleviated by oral fucoidan. Importantly, in this model, the macroscopic changes induced by oral fucoidan correlated significantly with substantially decreased production of at least 15 pro-inflammatory cytokines by the colon tissue. Overall, oral fucoidan preparations significantly reduce the inflammatory pathology associated with DSS-induced colitis and could therefore represent a novel nutraceutical option for the management of IBD.

Ho T.T.M.,University of South Australia | Bremmell K.E.,University of South Australia | Krasowska M.,University of South Australia | Stringer D.N.,Marinova Pty Ltd | And 2 more authors.
Soft Matter | Year: 2015

Fucoidan is a sulfated polysaccharide that is extracted primarily from seaweed. The polymer contains a natural variation in chemistry based upon the species of seaweed from which it is extracted. We have used two different fucoidans from two different seaweed species (Fucus vesiculosus - FV; and Undaria pinnatifida - UP) as polyanions for the formation of polysaccharide-based polyelectrolyte multilayers (PEMs), to determine if the chemistry of different fucoidans can be chosen to fine-tune the structure of the polymer film. Partially acetylated chitosan was chosen as the polycation for the work, and the presented data illustrate the effect of secondary hydrogen bonding interactions on PEM build-up and properties. Ellipsometry and quartz crystal microbalance with dissipation monitoring (QCM-D) measurements performed during film build-up enabled detailed measurements of layer thickness, adsorbed mass, and the dynamics of the multilayer formation process. High quality atomic force microscopy (AFM) images revealed the differences in morphology of the PEMs formed from the two fucoidans, and allowed for a more direct layer thickness measurement. X-ray photoelectron spectroscopy (XPS) confirmed the chemistry of the films, and an indication of the altered interactions between chitosan and fucoidan with variation in fucoidan type, but also with layer number. Distinct differences were observed between multilayers formed with the two fucoidans, with those constructed using UP having thinner, denser, less hydrated layers than those constructed using FV. These differences are discussed in the context of their varied chemistry, primarily their difference in molecular weight and degree of acetylation. This journal is © The Royal Society of Chemistry 2015.

Lowenthal R.M.,Menzies Research Institute | Fitton J.H.,Marinova Pty. Ltd.
Journal of Applied Phycology | Year: 2014

Is there a role for brown macroalgae-derived fucoidan in cancer therapeutics? This review discusses the in vitro, in vivo and clinical data concerning fucoidan and cancer. Fucoidans vary according to the species from which they are derived, making direct comparisons between studies difficult. Data from in vitro studies indicate direct activity against some cancer cell lines. In vivo studies indicate cancer inhibitory activity, which may also be partly attributable to increases in innate and specific immunity. A small number of preliminary clinical studies indicate activity and should be followed up. Lastly, to date, there is no reported research into potential interactions between chemotherapy and fucoidan. Other naturally derived pharmaceuticals are known to interfere with certain forms of chemotherapy, and this should not be overlooked during the development of fucoidan. © 2014 Springer Science+Business Media Dordrecht

Marinova Pty Ltd | Date: 2011-02-21

The present disclosure relates generally to the field of anti-viral therapy and prophylaxis. Formulations and agents are provided which inhibit viruses of the Orthomyxoviridae family and ameliorate symptoms and conditions caused by viral infection. The present disclosure teaches the control of influenza virus infection and spread and amelioration of conditions caused thereby. The formulations and agents may be processed as medicaments or as health supplements for more general application such as in the form of consumer goods or consumer foods.

Marinova Pty Ltd | Date: 2013-12-20

A method is provided for treating a seaweed extract having a target molecule and a pyrogenic agent. The method includes inactivating the pyrogenic agent and/or removing the pyrogenic agent. The method results in a reduction in pyrogenicity of the extract. The method is useful in the preparation of pharmaceutical compositions and biomaterials for which pyrogen removal is critical.

Loading Marinova Pty Ltd collaborators
Loading Marinova Pty Ltd collaborators